Clinical Cancer Research, Vol 3, Issue 6 861-865, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma

G Fontanini, S Vignati, L Boldrini, S Chine, V Silvestri, M Lucchi, A Mussi, CA Angeletti and G Bevilacqua
Department of Oncology, Division of Pathology and Department of Surgery, Service of Thoracic Surgery, University of Pisa, via Roma 57, 56126 Pisa, Italy.

Vascular endothelial growth factor (VEGF) plays a pivotal role in the development of neovascularization in both physiological and pathological processes, e.g., developmental and reproductive angiogenesis, proliferative retinopathies, and cancers. Several solid tumors produce ample amounts of VEGF, which stimulates proliferation and migration of endothelial cells, thereby inducing neovascularization by a paracrine mechanism. Recently, VEGF expression has been shown to significantly affect the prognosis of different kinds of human cancer. Because neoangiogenesis represents an important prognostic indicator of poor prognosis in non-small cell lung cancer (NSCLC), we investigated the influence of VEGF during progression of this type of cancer and its relationship to tumoral neovascularization. VEGF expression was significantly associated with new vessel formation (r = 0.44; P < 0.0001). Moreover, in univariate analysis, VEGF expression significantly affected overall and disease-free survival (P = 0.00003 and P = 0. 0004, respectively). Backward stepwise regression analysis indicated that VEGF expression was an independent prognostic factor in patients with NSCLC. These findings support the hypothesis that VEGF is an important angiogenic factor in primary NSCLC and may help in predicting the outcome of this group of cancers.

This article has been cited by other articles:

				R. Bianco, R. Rosa, V. Damiano, G. Daniele, T. Gelardi, S. Garofalo, V. Tarallo, S. De Falco, D. Melisi, R. Benelli, et al. Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells Clin. Cancer Res., August 15, 2008; 14(16): 5069 - 5080. [Abstract] [Full Text] [PDF]

				P. S. Hodkinson, A. MacKinnon, and T. Sethi Targeting Growth Factors in Lung Cancer Chest, May 1, 2008; 133(5): 1209 - 1216. [Abstract] [Full Text] [PDF]

				C.-S. Huang, J.-W. Liao, and M.-L. Hu Lycopene Inhibits Experimental Metastasis of Human Hepatoma SK-Hep-1 Cells in Athymic Nude Mice J. Nutr., March 1, 2008; 138(3): 538 - 543. [Abstract] [Full Text] [PDF]

				R. S. Herbst, V. J. O'Neill, L. Fehrenbacher, C. P. Belani, P. D. Bonomi, L. Hart, O. Melnyk, D. Ramies, M. Lin, and A. Sandler Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non Small-Cell Lung Cancer J. Clin. Oncol., October 20, 2007; 25(30): 4743 - 4750. [Abstract] [Full Text] [PDF]

				E. Zygalaki, E. G. Tsaroucha, L. Kaklamanis, and E. S. Lianidou Quantitative Real-Time Reverse Transcription PCR Study of the Expression of Vascular Endothelial Growth Factor (VEGF) Splice Variants and VEGF Receptors (VEGFR-1 and VEGFR-2) in Non Small Cell Lung Cancer Clin. Chem., August 1, 2007; 53(8): 1433 - 1439. [Abstract] [Full Text] [PDF]

				J. H. Park, K. J. Park, Y. S. Kim, S. S. Sheen, K. S. Lee, H. N. Lee, Y. J. Oh, and S. C. Hwang Serum Angiopoietin-2 as a Clinical Marker for Lung Cancer Chest, July 1, 2007; 132(1): 200 - 206. [Abstract] [Full Text] [PDF]

				Y. J. Jeong, C. A. Yi, and K. S. Lee Solitary Pulmonary Nodules: Detection, Characterization, and Guidance for Further Diagnostic Workup and Treatment Am. J. Roentgenol., January 1, 2007; 188(1): 57 - 68. [Abstract] [Full Text] [PDF]

				H. Yasuda, K. Nakayama, M. Watanabe, S. Suzuki, H. Fuji, S. Okinaga, A. Kanda, K. Zayasu, T. Sasaki, M. Asada, et al. Nitroglycerin Treatment May Enhance Chemosensitivity to Docetaxel and Carboplatin in Patients with Lung Adenocarcinoma. Clin. Cancer Res., November 15, 2006; 12(22): 6748 - 6757. [Abstract] [Full Text] [PDF]

				S. S. Shim, K. S. Lee, M. J. Chung, H. Kim, O J. Kwon, and S. Kim Do hemodynamic studies of stage t1 lung cancer enable the prediction of hilar or mediastinal nodal metastasis? Am. J. Roentgenol., April 1, 2006; 186(4): 981 - 988. [Abstract] [Full Text] [PDF]

				S. Yano, H. Muguruma, Y. Matsumori, H. Goto, E. Nakataki, N. Edakuni, H. Tomimoto, S. Kakiuchi, A. Yamamoto, H. Uehara, et al. Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice Clin. Cancer Res., December 15, 2005; 11(24): 8789 - 8798. [Abstract] [Full Text] [PDF]

				M. Numasaki, M. Watanabe, T. Suzuki, H. Takahashi, A. Nakamura, F. McAllister, T. Hishinuma, J. Goto, M. T. Lotze, J. K. Kolls, et al. IL-17 Enhances the Net Angiogenic Activity and In Vivo Growth of Human Non-Small Cell Lung Cancer in SCID Mice through Promoting CXCR-2-Dependent Angiogenesis J. Immunol., November 1, 2005; 175(9): 6177 - 6189. [Abstract] [Full Text] [PDF]

				H. S. Rugo, R. S. Herbst, G. Liu, J. W. Park, M. S. Kies, H. M. Steinfeldt, Y. K. Pithavala, S. D. Reich, J. L. Freddo, and G. Wilding Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results J. Clin. Oncol., August 20, 2005; 23(24): 5474 - 5483. [Abstract] [Full Text] [PDF]

				R. S. Herbst, A. Onn, and A. Sandler Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications J. Clin. Oncol., May 10, 2005; 23(14): 3243 - 3256. [Abstract] [Full Text] [PDF]

				H.-P. Gerber and N. Ferrara Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies Cancer Res., February 1, 2005; 65(3): 671 - 680. [Abstract] [Full Text] [PDF]

				C. Tuccillo, M. Romano, T. Troiani, E. Martinelli, F. Morgillo, F. De Vita, R. Bianco, G. Fontanini, R. A. Bianco, G. Tortora, et al. Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor Clin. Cancer Res., February 1, 2005; 11(3): 1268 - 1276. [Abstract] [Full Text] [PDF]

				O. G. Yigitbasi, M. N. Younes, D. Doan, S. A. Jasser, B. A. Schiff, C. D. Bucana, B. N. Bekele, I. J. Fidler, and J. N. Myers Tumor Cell and Endothelial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade Cancer Res., November 1, 2004; 64(21): 7977 - 7984. [Abstract] [Full Text] [PDF]

				C. A Yi, K. S. Lee, E. A Kim, J. Han, H. Kim, O J. Kwon, Y. J. Jeong, and S. Kim Solitary Pulmonary Nodules: Dynamic Enhanced Multi-Detector Row CT Study and Comparison with Vascular Endothelial Growth Factor and Microvessel Density Radiology, October 1, 2004; 233(1): 191 - 199. [Abstract] [Full Text] [PDF]

				J. F. Schaefer, J. Vollmar, F. Schick, R. Vonthein, M. D. Seemann, H. Aebert, R. Dierkesmann, G. Friedel, and C. D. Claussen Solitary Pulmonary Nodules: Dynamic Contrast-enhanced MR Imaging--Perfusion Differences in Malignant and Benign Lesions Radiology, August 1, 2004; 232(2): 544 - 553. [Abstract] [Full Text] [PDF]

				T C Mineo, V Ambrogi, A Baldi, C Rabitti, P Bollero, B Vincenzi, and G Tonini Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer J. Clin. Pathol., June 1, 2004; 57(6): 591 - 597. [Abstract] [Full Text] [PDF]

				F. Ciardiello, R. Bianco, R. Caputo, R. Caputo, V. Damiano, T. Troiani, D. Melisi, F. De Vita, S. De Placido, A. R. Bianco, et al. Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy Clin. Cancer Res., January 15, 2004; 10(2): 784 - 793. [Abstract] [Full Text] [PDF]

				D. Saha, K. R. Sekhar, C. Cao, J. D. Morrow, H. Choy, and M. L. Freeman The Antiangiogenic Agent SU5416 Down-Regulates Phorbol Ester-Mediated Induction of Cyclooxygenase 2 Expression by Inhibiting Nicotinamide Adenine Dinucleotide Phosphate Oxidase Activity Cancer Res., October 15, 2003; 63(20): 6920 - 6927. [Abstract] [Full Text] [PDF]

				K. Fujimoto, T. Abe, N. L. Muller, H. Terasaki, S. Kato, J. Sadohara, R. Kono, O. Edamitsu, T. Ishitake, A. Hayashi, et al. Small Peripheral Pulmonary Carcinomas Evaluated with Dynamic MR Imaging: Correlation with Tumor Vascularity and Prognosis Radiology, June 1, 2003; 227(3): 786 - 793. [Abstract] [Full Text] [PDF]

				F. Ciardiello, R. Caputo, V. Damiano, R. Caputo, T. Troiani, D. Vitagliano, F. Carlomagno, B. M. Veneziani, G. Fontanini, A. R. Bianco, et al. Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase Clin. Cancer Res., April 1, 2003; 9(4): 1546 - 1556. [Abstract] [Full Text] [PDF]

				E. Laack, A. Kohler, C. Kugler, T. Dierlamm, C. Knuffmann, G. Vohwinkel, A. Niestroy, N. Dahlmann, A. Peters, J. Berger, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer Ann. Onc., October 1, 2002; 13(10): 1550 - 1557. [Abstract] [Full Text] [PDF]

				M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]

				M. Lucchi, A. Mussi, G. Fontanini, P. Faviana, A. Ribechini, and C. A. Angeletti Small cell lung carcinoma (SCLC): the angiogenic phenomenon Eur. J. Cardiothorac. Surg., June 1, 2002; 21(6): 1105 - 1110. [Abstract] [Full Text] [PDF]

				A. P. Taylor, L. Osorio, R. Craig, J. A. Raleigh, Z. Ying, D. M. Goldenberg, and R. D. Blumenthal Tumor-specific Regulation of Angiogenic Growth Factors and Their Receptors during Recovery from Cytotoxic Therapy Clin. Cancer Res., April 1, 2002; 8(4): 1213 - 1222. [Abstract] [Full Text] [PDF]

				A. Yuan, C.-J. Yu, K.-T. Luh, S.-H. Kuo, Y.-C. Lee, and P.-C. Yang Aberrant p53 Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA and Interleukin-8 mRNA and Neoangiogenesis in Non-Small-Cell Lung Cancer J. Clin. Oncol., February 15, 2002; 20(4): 900 - 910. [Abstract] [Full Text] [PDF]

				J. Brognard, A. S. Clark, Y. Ni, and P. A. Dennis Akt/Protein Kinase B Is Constitutively Active in Non-Small Cell Lung Cancer Cells and Promotes Cellular Survival and Resistance to Chemotherapy and Radiation Cancer Res., May 1, 2001; 61(10): 3986 - 3997. [Abstract] [Full Text]

				R. T.-P. Poon, S.-T. Fan, and J. Wong Clinical Implications of Circulating Angiogenic Factors in Cancer Patients J. Clin. Oncol., February 15, 2001; 19(4): 1207 - 1225. [Abstract] [Full Text] [PDF]

				M. S. Gordon, K. Margolin, M. Talpaz, G. W. Sledge Jr, E. Holmgren, R. Benjamin, S. Stalter, S. Shak, and D. C. Adelman Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer J. Clin. Oncol., February 1, 2001; 19(3): 843 - 850. [Abstract] [Full Text] [PDF]

				A. Yuan, C.-J. Yu, S.-H. Kuo, W.-J. Chen, F.-Y. Lin, K.-T. Luh, P.-C. Yang, and Y.-C. Lee Vascular Endothelial Growth Factor 189 mRNA Isoform Expression Specifically Correlates With Tumor Angiogenesis, Patient Survival, and Postoperative Relapse in Non-Small-Cell Lung Cancer J. Clin. Oncol., January 15, 2001; 19(2): 432 - 441. [Abstract] [Full Text] [PDF]

				R. S. Herbst and I. J. Fidler Angiogenesis and Lung Cancer: Potential for Therapy Clin. Cancer Res., December 1, 2000; 6(12): 4604 - 4606. [Full Text]

				A. J. Marrogi, W. D. Travis, J. A. Welsh, M. A. Khan, H. Rahim, H. Tazelaar, P. Pairolero, V. Trastek, J. Jett, N. E. Caporaso, et al. Nitric Oxide Synthase, Cyclooxygenase 2, and Vascular Endothelial Growth Factor in the Angiogenesis of Non-Small Cell Lung Carcinoma Clin. Cancer Res., December 1, 2000; 6(12): 4739 - 4744. [Abstract] [Full Text]

				D. Salani, V. Di Castro, M. R. Nicotra, L. Rosano, R. Tecce, A. Venuti, P. G. Natali, and A. Bagnato Role of Endothelin-1 in Neovascularization of Ovarian Carcinoma Am. J. Pathol., November 1, 2000; 157(5): 1537 - 1547. [Abstract] [Full Text] [PDF]

				F. Ciardiello, R. Bianco, V. Damiano, G. Fontanini, R. Caputo, G. Pomatico, Sabino De Placido, A. R. Bianco, J. Mendelsohn, and G. Tortora Antiangiogenic and Antitumor Activity of Anti-Epidermal Growth Factor Receptor C225 Monoclonal Antibody in Combination with Vascular Endothelial Growth Factor Antisense Oligonucleotide in Human GEO Colon Cancer Cells Clin. Cancer Res., September 1, 2000; 6(9): 3739 - 3747. [Abstract] [Full Text]

				R. E. Favoni and A. De Cupis The Role of Polypeptide Growth Factors in Human Carcinomas: New Targets for a Novel Pharmacological Approach Pharmacol. Rev., June 1, 2000; 52(2): 179 - 206. [Abstract] [Full Text] [PDF]

				Y. Ohta, H. Nozawa, Y. Tanaka, M. Oda, and Y. Watanabe INCREASED VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR-C AND DECREASED NM23 EXPRESSION ASSOCIATED WITH MICRODISSEMINATION IN THE LYMPH NODES IN STAGE I NON-SMALL CELL LUNG CANCER J. Thorac. Cardiovasc. Surg., April 1, 2000; 119(4): 804 - 813. [Abstract] [Full Text] [PDF]

				Y. Ohta, Y. Tomita, M. Oda, S. Watanabe, S. Murakami, and Y. Watanabe Tumor angiogenesis and recurrence in stage I non-small cell lung cancer Ann. Thorac. Surg., September 1, 1999; 68(3): 1034 - 1038. [Abstract] [Full Text] [PDF]

				G. Fontanini, L. Boldrini, A. Calcinai, S. Chine, M. Lucchi, A. Mussi, C. A. Angeletti, F. Basolo, and G. Bevilacqua Thrombospondins I and II Messenger RNA Expression in Lung Carcinoma: Relationship with p53 Alterations, Angiogenic Growth Factors, and Vascular Density Clin. Cancer Res., January 1, 1999; 5(1): 155 - 161. [Abstract] [Full Text] [PDF]